A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Research Article
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002374 August 8, 2017
Community Health Impact Coalition members & colleagues from across the world are sharing COVID-19 explainers, internal policies, clinical protocols, & more live
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad sp...ectrum Pan-African polyvalent antivenoms: products that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Clinical management handbook
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11